SMYD2
| Official symbol: | SMYD2 |
| Full name: | SET and MYND domain containing 2 |
| Location: | 1q32.3 |
| Also known as: | KMT3C, HSKM-B, ZMYND14 |
| Entrez ID: | 56950 |
| Ensembl ID: | ENSG00000143499 |
| Summary: | SET domain-containing proteins, such as SMYD2, catalyze lysine methylation (Brown et al., 2006 [PubMed 16805913]).[supplied by OMIM, Nov 2008] |
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
|
|
|
| |
|
|
|
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
| Gscore (Amp): | 0.00 | | Gscore (Del): | 0.38 |
|
|
|
| Recurrently deleted in 2 cancer type(s) |
|
| |
|
|
|
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
|
|
|
| |
|
|
|
| |
Overall
|
|
Tissue specific
|
| |
| Total fusion occurrence: | 4 |
|
|
| Fusions detected in 4 cancer type(s) |
|
| |
|
|
|
| Functional class: | Epigenetic |
| JensenLab PubMed score: | 52.67 (Percentile rank: 63.12%) |
| PubTator score: | 30.38 (Percentile rank: 59.78%) |
| Target development/druggability level: | TchemThese targets have activities in ChEMBL or DrugCentral that satisfy the activity thresholds detailed below. |
| Tractability (small molecule): | Discovery PrecedenceTargets with ligands; Targets with crystal structures with ligands |
| Tractability (antibody): | |
